NCT01658956

Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia

A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 142 (estimated)
• Sponsor: Jules Bordet Institute · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile neutropenia among patients with breast cancer, treated with chemotherapy and presenting with a low to moderate risk of developing febrile neutropenia.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	GCSF administration on days 8 and 12 after chemotherapy

Timeline

• Start date: 2012-07-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2012-08-07
• Last updated: 2015-01-06

Locations

1 site across 1 country: Belgium